SUSTIVA

Compare SUSTIVA  to:
Compare
Compare

Generic Name for SUSTIVA

Efavirenz 50mg, 100mg, 200mg; caps.

Legal Classification:

Rx

Pharmacological Class for SUSTIVA

Non-nucleoside reverse transcriptase inhibitor.

Manufacturer of SUSTIVA

Bristol-Myers Squibb Virology

Indications for SUSTIVA

HIV-1 infection.

Adults and Children:

Give once daily on an empty stomach, preferably at bedtime. Consider pretreating with antihistamine (for children) or steroid to minimize rash. <3years: not recommended. ≥3years (10kg to <15kg): 200 mg; (15kg to <20kg): 250mg; (20kg to <25kg): 300mg; (25kg to <32.5kg): 350mg; (32.5kg to <40kg): 400mg; (≥40kg) and adults: 600mg.

Also:

Contraindications for SUSTIVA

Concomitant cisapride, ergots, midazolam, triazolam, voriconazole.

Warnings/Precautions for SUSTIVA

CNS or psychiatric disturbances. Seizures. Hepatic dysfunction. Monitor cholesterol and triglycerides; monitor liver function in suspected or known history of hepatitis B or C. Discontinue if severe rash (w. blistering, desquamation, mucosal involvement, or fever) occurs. Obtain (–) pregnancy test before starting; use adequate (barrier + hormonal) contraception. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for SUSTIVA

See Contraindications. Avoid alcohol, other psychoactive and/or hepatotoxic drugs. Antagonized by St. John's wort: not recommended. Caution with drugs metabolized by, or that affect activity of, CYP2C9, CYP2C19, CYP3A4. Efavirenz levels decreased by phenobarbital, rifampin, rifabutin. May decrease levels of indinavir (increase indinavir to 1g every 8 hours), amprenavir, clarithromycin, methadone, rifabutin (increase dose: see literature). Efavirenz increases nelfinavir, ethinyl estradiol plasma levels. Levels of both drugs increased with ritonavir (monitor liver function and for adverse events). Levels of both drugs are decreased with saquinavir (do not use as sole protease inhibitor). Closely monitor warfarin, anticonvulsants (esp. phenytoin, phenobarbital, carbamazepine), rifabutin, others. May cause false (+) cannabis screening test (CEDIA DAU multi-level THC assay).

Adverse Reactions for SUSTIVA

CNS effects (eg, drowsiness, dizziness, insomnia, impaired concentration, abnormal dreams), psychiatric effects (eg, severe depression, suicidal ideation/attempt, aggression, paranoia, mania, delusions, psychosis), rash (may be severe; eg, Stevens-Johnson, erythema multiforme), GI upset, fever, cough, dyspnea, redistribution of body fat.

Notes for SUSTIVA

Register pregnant patients exposed to efavirenz by calling (800) 258-4263.

How is SUSTIVA supplied?

Caps 50mg, 100mg—30
200mg—90
Tabs 600mg—30

Related Disease:

HIV~antivirals

Related Resources

Abbott RealTime HBV test approved

September 02, 2010

Abbott announced that the FDA has approved its RealTime HBV assay for measuring the amount of hepatitis B virus (HBV) in human plasma or serum from individuals chronically infected with HBV.

Longer use of Valcyte for renal transplant patients approved

August 11, 2010

The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.

Phase 3 study of boceprevir for the treatment of HCV

August 05, 2010

Merck announced the completion and results of its two Phase 3 studies for boceprevir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection.

Afluria labeling updated to include fever and febrile seizure risk

August 02, 2010

The Prescribing Information for Afluria (trivalent, inactivated, "split virus" influenza vaccine [Types A and B], from CSL Biotherapies) has been updated to inform healthcare professionals of an increased incidence of fever and febrile seizure among young children in Australia, mainly those <5years of age.

Fluzone available for 2010-2011 influenza season

July 30, 2010

Sanofi Pasteur announced that it has begun shipping the 2010-2011 formulation of Fluzone (trivalent inactivated "split virus" influenza vaccine [Types A and B]).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions